2Macular Photocogulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Arch Ophthalmol, 1991, 109: 1242-1257.
3Treatment of Age-related Macular Degeneration with Photodynamic Therapy(TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol,1999,117:1329-1345.
4TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol,2001,119:198-207.
5VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in p
6VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia:2-year results of a randomized clinical trial-VIP report No.3.Ophthalmology,2003,110:667-673.
7Rogers AH, Duker JS, Nichols N, et al. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology,2003,110:1315-1320.
8Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology, 2003, 110: 1306-1314.
9Schmidt-Erfurth U, Laqua H, Schlotzer- Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol, 2002,120:835-844.
10American Academy of Ophthalmology. Photodynamic therapy with verteporfin for age-related macular degeneration. Ophthalmology, 2000,107:2314-2317.
6Loo R H,Scott I U,Flynn H W Jr,et al.Factors associated with reduced visual acuity during long-term follow-up patients with idiopathic central serous chorioretinopathy[J].Retina,2002,22(1):19-24.
